All Posts By

Frank DeMaria

Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors

By Portfolio News, Ladder Bio
Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform BLUE BELL, Pa.--(BUSINESS WIRE)--Ladder Bio, Inc., a structure-guided biotechnology company developing Spiroligomers™, a new class of chemical matter as medicines, today announced the appointments of Jay Fine, PhD, and John Prufeta…
Read More

Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations

By Portfolio News, Latus
Financing extension led by 8VC to advance LTS-201 as a potential significant commercial opportunity in Huntington’s disease (IND expected in 3Q 2026) Potential clinical proof-of-concept of Latus platform from LTS-101 in CLN2 disease expected in 4Q 2026; multiple fast follow-ons utilize the same capsid for larger indications Proprietary engineered AAV…
Read More

The Future of Healthcare Runs on AI-Powered Automation and Data — Here’s How One Company Is Making It a Reality

By Bainbridge Health, Portfolio News
Healthcare is entering a new era filled with opportunity. Hospitals are exploring smarter ways to care for patients with the staff they have. Pharmaceutical companies are rethinking how to bring therapies to market with greater speed and precision. Across the industry, one theme is clear: AI-powered automation and data are…
Read More

Investing in a Healthier Future: How Atalan Is Enabling Health Systems to Predict and Prevent Surprise Resignations and Protect Revenue

By Portfolio News, Atalan
Atalan is Pioneering the Clinician Retention Intelligence (CRI) Category in Healthcare Healthcare systems thrive when clinicians do. Atalan, a healthcare workforce technology company, is leading the way in helping hospitals and health systems protect revenue, retain clinicians, and sustain high-quality patient care. With over 60% of physicians and nearly half…
Read More